Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 604

1.

Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.

Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, Llor C; EVAN Study Group..

Clin Infect Dis. 2006 Oct 1;43(7):860-8.

2.

Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects.

Vila-Córcoles A, Ochoa-Gondar O, Llor C, Hospital I, Rodríguez T, Gómez A.

Eur Respir J. 2005 Dec;26(6):1086-91.

3.

Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink..

N Engl J Med. 2003 May 1;348(18):1747-55.

4.

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study.

Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, Hospital I, Gomez-Bertomeu F, Raga X.

Vaccine. 2009 Mar 4;27(10):1504-10. doi: 10.1016/j.vaccine.2009.01.013.

PMID:
19171174
5.

Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.

Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR.

Clin Infect Dis. 2010 Jul 1;51(1):15-22. doi: 10.1086/653114.

6.

Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up.

Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A, Gomez F, Raga X, de Diego C, Satue E, Salsench E; EPIVAC Study Group..

BMC Public Health. 2012 Mar 22;12:222. doi: 10.1186/1471-2458-12-222.

7.

Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study.

Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, Raga X, Gomez F, Valdivieso E, Fuentes C, Palacios L; EVAN Study Group..

Vaccine. 2008 Apr 7;26(16):1955-62. doi: 10.1016/j.vaccine.2008.02.021.

PMID:
18343541
8.

Advances in pneumococcal vaccines: what are the advantages for the elderly?

Vila-Córcoles A.

Drugs Aging. 2007;24(10):791-800. Review.

PMID:
17896829
9.

Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial.

Koivula I, Stén M, Leinonen M, Mäkelä PH.

Am J Med. 1997 Oct;103(4):281-90.

PMID:
9382120
10.

Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity.

Christenson B, Pauksen K, Sylvan SP.

Virol J. 2008 Apr 28;5:52. doi: 10.1186/1743-422X-5-52.

11.

Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.

Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I.

Clin Infect Dis. 2014 Apr;58(7):909-17. doi: 10.1093/cid/ciu002.

12.

Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study.

Ansaldi F, Turello V, Lai P, Bastone G, De Luca S, Rosselli R, Durando P, Sticchi L, Gasparini R, Delfino E, Icardi G.

J Int Med Res. 2005 Sep-Oct;33(5):490-500.

PMID:
16222881
13.

Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study.

Peñaranda M, Falco V, Payeras A, Jordano Q, Curran A, Pareja A, Samperiz G, Dalmau D, Ribera E, Riera M.

Clin Infect Dis. 2007 Oct 1;45(7):e82-7.

14.

Clinical effectiveness of pneumococcal polysaccharide vaccine in men: California Men's Health Study.

Hechter RC, Chao C, Jacobsen SJ, Slezak JM, Quinn VP, Van Den Eeden SK, Tseng HF.

Vaccine. 2012 Aug 17;30(38):5625-30. doi: 10.1016/j.vaccine.2012.06.085.

PMID:
22789510
15.

Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.

Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, de Diego C, Salsench E, Raga X, Fuentes-Bellido CM.

BMC Public Health. 2010 Jan 19;10:25. doi: 10.1186/1471-2458-10-25.

16.

Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.

Johnstone J, Marrie TJ, Eurich DT, Majumdar SR.

Arch Intern Med. 2007 Oct 8;167(18):1938-43.

PMID:
17923592
17.

The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease.

Nichol KL, Baken L, Wuorenma J, Nelson A.

Arch Intern Med. 1999 Nov 8;159(20):2437-42.

PMID:
10665892
18.
19.

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004.

Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, Ahmed S, Robertson C, Clarke SC.

BMC Infect Dis. 2008 Apr 23;8:53. doi: 10.1186/1471-2334-8-53.

20.

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study.

Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A; EPIVAC Study Group..

Hum Vaccin Immunother. 2012 May;8(5):639-44. doi: 10.4161/hv.19466.

PMID:
22634442
Items per page

Supplemental Content

Support Center